MAT Act of 2026
The source supplies the latest action, but no lifecycle stage.
Latest action (16 Jul 2026): Referred to the House Committee on the Judiciary.
What this bill does
H.R. 9756, the "Maternal Access to Treatment Act of 2026" (MAT Act of 2026), would require the Director of the Bureau of Prisons to provide medication assisted treatment (MAT) for opioid addiction to pregnant women who are in federal custody and addicted to opioids. The bill includes an exception allowing a mentally competent pregnant woman to decline this treatment if she chooses.
The bill would primarily affect pregnant women incarcerated in federal prisons who struggle with opioid addiction, as well as the Bureau of Prisons, which would be responsible for implementing and administering the treatment mandate. It does not address treatment for other incarcerated individuals, nor does it specify funding, timelines, or additional details about how the treatment program would be structured or monitored.
The bill was introduced in the House on July 16, 2026, by Rep. John J. McGuire of Virginia and has been referred to the House Committee on the Judiciary for consideration. As a newly introduced bill, it would need to be reviewed, potentially amended, and voted on by the committee and then the full House before advancing to the Senate. Its current status reflects an early stage in the legislative process, and its eventual passage or further changes remain uncertain.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Timeline
16 Jul 2026
Referred to the House Committee on the Judiciary.
Common questions
- What does H.R. 9756 do?
- H.R. 9756, the "Maternal Access to Treatment Act of 2026" (MAT Act of 2026), would require the Director of the Bureau of Prisons to provide medication assisted treatment (MAT) for opioid addiction to pregnant women who are in federal custody and addicted to opioids. The bill includes an exception allowing a mentally competent pregnant woman to decline this treatment if she chooses. The bill would primarily affect pregnant women incarcerated in federal prisons who struggle with opioid addiction, as well as the Bureau of Prisons, which would be responsible for implementing and administering the treatment mandate. It does not address treatment for other incarcerated individuals, nor does it specify funding, timelines, or additional details about how the treatment program would be structured or monitored. The bill was introduced in the House on July 16, 2026, by Rep. John J. McGuire of Virginia and has been referred to the House Committee on the Judiciary for consideration. As a newly introduced bill, it would need to be reviewed, potentially amended, and voted on by the committee and then the full House before advancing to the Senate. Its current status reflects an early stage in the legislative process, and its eventual passage or further changes remain uncertain.
- Has H.R. 9756 become law?
- The source does not supply a confirmed lifecycle stage for H.R. 9756. Check the latest action and official source below.
- Who sponsored H.R. 9756?
- H.R. 9756 was sponsored by Rep. McGuire, John J. [R-VA-5] (R-VA), with 0 cosponsors.
- What's the latest action on H.R. 9756?
- Referred to the House Committee on the Judiciary. (16 Jul 2026).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
340B Rebate Model Delay Act
Lower Premiums, Faster Payments Act
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.